Consensus of the Brazilian society of infectious diseases on the management and treatment of hepatits C

Brazilian Journal of Infectious Diseases

Volumn 11, Issue 5, 2007, Pages 446-

  de Araújo, Evaldo Stanislau Affonso ^a   Mendonça, João Silva ^b   Barone, Antonio Alci ^a   Gonçales Jr , Fernando Lopes ^c   Ferreira, Marcelo Simão ^c   Focaccia, Roberto ^c   Pawlotsky, Jean Michel ^c   Rodrigues Viso, Ana Tereza ^c   Vigani, Aline ^c   Oliveira, André Cosme ^c   de Melo, Carlos Eduardo ^c   Alves, Carlos Brites ^c   Diament, Décio ^c   Abdala, Edson ^c   De Bortholi, Edgard ^c   de Mello, Evandro Sobroza ^c   Gonçalves, Eduardo Sellan ^c   Tengan, Fátima Mitiko ^a   Mitre, Heloisa Pedrosa ^c   Prado, Kleber Dias ^c   Gonçales, Neiva Sellan ^c   Cavalheiro, Norma de Paula ^a,c   Siciliano, Rinaldo Focaccia ^c   Angerami, Rodrigo Nogueira ^c   de Oliveira, Umbeliana Barbosa ^c   Ferreira Alves, Venâncio Avancini ^c   more..

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALPHA INTERFERON; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; CORTICOSTEROID; DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ERYTHROPOIETIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE PLUS ZIDOVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ABACAVIR; CD4 ANTIGEN; HEPATITIS C VACCINE;

ANEMIA; ARTICLE; BRAZIL; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CYTOPENIA; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; HEALTH CARE POLICY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER FIBROSIS; LOW DRUG DOSE; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MONOTHERAPY; NEUTROPENIA; OBESITY; PATIENT COMPLIANCE; PATIENT MONITORING; RECOMMENDED DRUG DOSE; STANDARD; THROMBOCYTOPENIA; VIRUS RESISTANCE; BIOSAFETY; BLOOD ANALYSIS; BREAST FEEDING; CD4+ T LYMPHOCYTE; CESAREAN SECTION; CHILDBIRTH; COMORBIDITY; CONSENSUS DEVELOPMENT; DISEASE SEVERITY; DRUG INDUSTRY; ECHOGRAPHY; EMERGENCY HEALTH SERVICE; GASTROINTESTINAL ENDOSCOPY; HEALTH PRACTITIONER; HEPATITIS C VIRUS; INDIVIDUALIZATION; INFECTION PREVENTION; INSULIN RESISTANCE; LIVER CIRRHOSIS; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; PATIENT ATTITUDE; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREGNANCY; RELAPSE; SENSITIVITY AND SPECIFICITY; SEXUAL TRANSMISSION; TREATMENT DURATION; TREATMENT INDICATION; VAGINAL DELIVERY; VIRUS LOAD; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; BRAZIL; HEPATITIS C; HUMANS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 36148945241     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)